Taken together, our results position IFNγ as a key mediator of tumor inhibition and strongly suggest that IFNγ production, rather than direct CD8+ T cell cytotoxicity, is required for therapeutic response to DCP-IL-12/FLT3L. The gene discussed is CD8A; the disease is neoplasm.